Searched for
WOCKHARDT MEDICINES
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Wockhardt under NPPA lens over essential blood pressure medicine priceThe medicines in question are methyldopa 250 mg and methyldopa 500 mg and both of these are currently under price control.
- Wockhardt's Daman plant GMP compliant: UK MHRA"Our manufacturing unit at Kadaiya Daman complies with the principles and guidelines of good manufacturing practices," Wockhardt said in a ...
- Delhi HC stays ban on drugs of Wockhardt, Glaxo and GriffonThe court also issued notice to the government on the companies' pleas challenging the notification and listed the petitions for hearing on...
- Wockhardt's Chikalthana plant gets GMP certificate from UKMHRAIn a major relief to drug firm Wockhardt, its Chikalthana plant at Aurangabad in Maharashtra has received a good manufacturing practice cer...
- UK MHRA completes inspection of Wockhardt's Chikalthana plantWockhardt said the UK health regulator has completed inspection of its plant at Chikalthana without issuing any critical observations on th...
- Zoher Sihorwala to head Wockhardt's regulatory unitMumbai-based pharmaceutical company Wockhardt has appointed Zoher Sihorwala to head its regulatory and compliance division, a senior execut...
- Wockhardt plunges 14% as USFDA issues import alert on Chikalthana PlantThe Chikalthana facility received ‘483’ observations after the USFDA raised several concerns. This is the second plant in India to get impo...
- Wockhardt rallies 11% after UK regulator eased restrictions on Kadiya unitUKMHRA had imposed restrictions on import of medicines made at the Mumbai-based firm's unit at Kadaiya for violation of norms.
- Wockhardt may face £1 million hit due to Kadaiya unit lapsesWockhardt today said it will take a revenue hit of nearly one million pounds due to import restrictions imposed by the UK health regulator ...
- Wockhardt drops 5%, locked in lower circuit as UK health regulator withdraws certificationThe stock is now locked in lower circuit at Rs 499.30. It has lost nearly 10% in the month of October as compared to over 60% fall so far i...
- UK health regulator withdraws certification of Wockhardt unitThe impact of the same on existing business will only be known once the company receives further communication from UKMHRA, Wockhardt said.
- Wockhardt gets warning letter from USFDA over Waluj plantWockhardt said it has received a warning letter from US health regulator over its facility at Waluj in Maharashtra not meeting manufacturin...
- UK regulator MHRA recalls 16 drugs made at Wockhardt's Waluj plantMHRA today said it has issued a precautionary recall for sixteen medicines made by Wockhardt at its Waluj unit due to manufacturing shortco...
- Gvernment bans sale of painkillerThe government has banned the sale of pain-relieving medicine, dextropropoxyphene, in a move that is expected to impact pharma companies' b...
- Wockhardt in talks to out-license research moleculesWockhardt is likely to out-license some of its research molecules to global pharma companies.
Load More
